| Literature DB >> 35889126 |
Fred Stephen Sarfo1,2, Albert Dompreh3, Shadrack Osei Asibey2, Richard Boateng3, Felix Weinreich4, Edmund Osei Kuffour5, Betty Norman1,2, Veronica Di Cristanziano6, Hagen Frickmann4,7, Torsten Feldt8, Kirsten Alexandra Eberhardt9,10.
Abstract
BACKGROUND: There is a paucity of information on the contemporary burden, disease patterns, and immunological profile of people living with HIV who are co-infected with C. cayetanensis in the post-antiretroviral therapy era.Entities:
Keywords: Africa; Sub-Sahara; cyclosporiasis; diarrhea; enteric infection; epidemiology; immunodeficiency; parasite
Year: 2022 PMID: 35889126 PMCID: PMC9316080 DOI: 10.3390/microorganisms10071407
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Prevalence of C. cayetanensis according to cohort characteristics. cART—combined antiretroviral therapy.
Demographical and socioeconomic parameters as well as medical treatment in HIV-infected individuals according to C. cayetanensis status.
| Variable | HIV-Positive | HIV-Positive | ||
|---|---|---|---|---|
| Demographics | Age in years ± SD | 39.0 ± 9.2 | 40.7 ± 9.5 | 0.208 |
| Female, | 37 (67.27) | 425 (74.43) | 0.321 | |
| Socioeconomic | Access to tap water, | 30 (54.55) | 303 (53.06) | 0.945 |
| Electricity in household, | 54 (98.18) | 531 (92.99) | 0.230 | |
| Television in household, | 47 (85.45) | 464 (81.26) | 0.559 | |
| Refrigerator in household, | 39 (70.91) | 415 (72.68) | 0.902 | |
| Owning a car, | 4 (7.27) | 56 (9.81) | 0.809 | |
| Medical therapy | Co-trimoxazole prophylaxis, | 14 (26.92) | 189 (33.69) | 0.402 |
| Antiretroviral therapy, | 19 (34.55) | 242 (42.38) | 0.326 | |
| Months since initiation of cART, median (IQR) | 17.3 (6.9–36.6) | 55.2 (28.6–79.5) | 0.001 |
SD—standard deviation; cART—combined antiretroviral therapy.
Figure 2Prevalence of clinical symptoms during the last six months according to C. cayetanensis status among HIV-positive participants. * p < 0.05; *** p < 0.001.
Virological and immunological parameters according to C. cayetanensis status in all HIV-positive patients and stratified by cART exposure.
| Variable | HIV-Positive Cohort | HIV-Positive cART Exposed | HIV Positive cART Naïve | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Viral load, log10 copies/mL | 5.0 (2.2–5.6) | 4.1 (1.6–5.3) | 0.012 | 1.6 (0.0–1.9) | 1.6 (0.0–1.9) | 0.126 | 5.4 (4.8–5.8) | 5.1 (4.3–5.6) | 0.054 |
| CD4+ T-cell count/µL | 228.0 (91.5–395.5) | 355.0 (163.5–586.5) | 0.001 | 308.0 (259.5–599.5) | 516.5 (329.0–712.8) | 0.053 | 141.0 (46.0–297.8) | 246.0 (94.0–451.0) | 0.012 |
| CD8+ T-cell count/µL | 938.0 (565.5–1279.0) | 977.0 (659.5–1390.5) | 0.576 | 896.0 (796.0–1172.0) | 961.0 (656.2–1331.2) | 0.961 | 988.0 (493.5–1388.0) | 995.0 (661.5–1507.5) | 0.477 |
| CD4+/CD8+ T-cell ratio | 0.3 (0.1–0.4) | 0.4 (0.2–0.7) | 0.005 | 0.4 (0.3–0.6) | 0.5 (0.4–0.9) | 0.205 | 0.2 (0.1–0.3) | 0.3 (0.1–0.5) | 0.013 |
| HLA-DR+ CD38+ CD4+ (%) | 31.0 (19.2–38.6) | 17.3 (9.5–30.6) | 0.002 | 16.4 (15.4–26.1) | 10.5 (6.5–18.2) | 0.018 | 33.4 (23.9–38.7) | 23.6 (13.7–35.9) | 0.043 |
| HLA-DR+ CD38+ CD8+ (%) | 49.3 (42.8–60.9) | 43.4 (27.8–56.7) | 0.042 | 45.6 (34.4–52.3) | 27.5 (19.4–38.1) | 0.045 | 54.0 (43.3–62.7) | 51.5 (41.3–64.7) | 0.565 |
| CD57+ CD4+ (%) | 19.2 (9.2–30.3) | 14.4 (8.8–23.9) | 0.293 | 16.9 (13.1–30.9) | 13.3 (8.5–20.7) | 0.274 | 19.5 (8.5–25.3) | 14.4 (9.1–26.5) | 0.726 |
| CD57+ CD8+ (%) | 46.9 (33.8–63.2) | 48.4 (38.4–57.3) | 0.816 | 39.0 (30.9–63.8) | 51.2 (43.2–58.5) | 0.227 | 52.9 (34.7–59.7) | 44.8 (35.5–55.6) | 0.480 |
| PD-1+ CD4+ (%) | 42.3 (29.8–63.2) | 32.4 (22.6–46.1) | 0.069 | 40.6 (22.3–53.8) | 30.0 (18.7–39.9) | 0.227 | 42.3 (30.2–66.1) | 36.5 (24.6–52.8) | 0.201 |
| PD-1+ CD8+ (%) | 43.1 (30.1–49.2) | 31.9 (21.4–44.0) | 0.042 | 38.0 (26.1–49.3) | 25.0 (15.5–36.0) | 0.074 | 44.6 (35.1–47.0) | 38.7 (26.0–50.3) | 0.334 |
| Ki67+ CD4+ (%) | 23.8 (14.7–26.8) | 13.0 (6.3–30.6) | 0.174 | 15.3 (10.7–21.1) | 7.9 (5.1–16.4) | 0.404 | 25.1 (17.0–42.3) | 21.1 (9.6–44.7) | 0.492 |
| Ki67+ CD8+ (%) | 16.0 (10.9–19.4) | 10.2 (6.2–17.2) | 0.153 | 21.7 (21.7–21.7) | 6.7 (4.0–12.2) | 0.219 | 14.0 (10.3–17.8) | 12.0 (8.1–18.7) | 0.658 |
cART—combined antiretroviral therapy; IQR—interquartile range.